If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics should suffice.

Yesterday, the company announced a new R&D partnership with precision medicine company Mirador Therapeutics, granting the biotech a license to use a "targeted set of aggregated, de-identified ...

On the sidelines of this year’s J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Mark McKenna, CEO of Mirador Therapeutics, a member of ...

The company aims to enter the clinic this year. Mirador Therapeutics is not making immunology and inflammation medicines for today. CEO Mark McKenna wants to be the creator of 2030’s great ...

Get Access To Every Broadway Story Unlock access to every one of the hundreds of articles published daily on BroadwayWorld by logging in with one click. MIRADOR, the new band co-founded by Greta ...

Plus Therapeutics shares are trading higher by 244% during Thursday's session. The company announced that the FDA accepted the name REYOBIQ for the company's lead asset. The ‘Trade of the Day ...

Company to host a conference call and webcast today at 8:30 a.m. ET and will be joined by key opinion leader, Professor Jacky Smith Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto ...

Viking Therapeutics (NASDAQ:VKTX) traded higher in the premarket on Tuesday after the company announced a multi-year production agreement with the contract manufacturer CordenPharma to support the ...

HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for ...